MDR: It’s Not the End of the World for Medtech Companies

article image

The new MDR heralds the beginning of a more regulated era in the medical device industry and with that come concerns about the requirements and costs that it imposes. But MDR doesn’t have to strike fear in the hearts and minds of medtech executives. Here are proven tools that companies can employ in order to ensure a smoother and less costly transition to the new MDR system. By Gloria Crispino, PhD, StatisticaMedica.

The new EU Medical Device Regulation (MDR), which is set to become effective on May 26, 2020, has sparked an uproar of worry throughout the medtech industry regarding the increased time and costs that the new rules will impose. High on the list of concerns is that the new rules will result in companies no longer looking to get CE marking for innovative technologies and introduce them in Europe first, meaning European patients will lag behind those in other nations in getting access to these life-saving devices.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: